Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Late annual account NBB
Fiscal year 2023 was filed 222 days after the legal deadline.
-
Annual account missing NBB
Fiscal year 2024 was expected before 31 July 2025 and has not been filed.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2023
BIOGENOSIS from Liège, company number BE0500705585, closed financial year 2023 with a result of € 79,471 after tax. For that financial year BIOGENOSIS recorded a gross margin of € -4,377 and equity of € 13 million. Compared with financial year 2022, the result moved from € -3,287 to € 79,471. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 10, 2025.
€ 13 million
▲ 1% vs 2022
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 79,471
▲ still € 3,287 loss in 2022
Profit after tax over the fiscal year.
€ 19,616
▼ 30% vs 2022
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2023. Retained profit grew to € -250,015.
People and assets in 2023
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2023
€ 3.4 million
▲ € 3.4 million vs 2022
Loans from banks and other lenders, long and short.
€ 7,878
▲ 70% vs 2022
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | Change 2022 → 2023 | |
|---|---|---|---|---|
| Gross margin | € -13,425 | € -1,807 | € -4,377 | ▼ € 2,570 |
| Profit after taxes | € -18,092 | € -3,287 | € 79,471 | ▲ € 82,757 |
| Equity | € 12,928,567 | € 12,925,280 | € 13,004,751 | ▲ 1% |
| Total debts | € 37,359 | € 41,154 | € 3,403,764 | ▲ € 3.4 million |
| Cash | € 27,980 | € 27,968 | € 19,616 | ▼ 30% |
| Retained profit | € -326,199 | € -329,486 | € -250,015 | ▲ € 79,471 |
| Bank debt | € 484 | € 484 | € 3,395,886 | ▲ € 3.4 million |
| Balance sheet total | € 12,965,927 | € 12,966,434 | € 16,408,515 | ▲ 27% |
Key figures of BIOGENOSIS, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.
What happened to BIOGENOSIS?
What happened at BIOGENOSIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jean Michel Foidart stepped down as director. NBB
- Pieter Van Rompay stepped down as director. NBB
- Stijn Van Rompay stepped down as director. NBB
- New annual accounts for financial year 2023: profit of € 79,471. filed late Source: NBB ↗
- Jean Michel Foidart became a director. NBB
- Pieter Van Rompay became a director. NBB
- Stijn Van Rompay became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 18,092 loss in 2021 to € 79,471 profit in 2023.
Best year ever: 2023, with € 79,471 profit.
A new publication or filing at BIOGENOSIS? We notify you, reason included.
Follow BIOGENOSISDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of SVR INVEST, SAFFELBERG INVESTMENTS, OUSIA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIOGENOSISThe shares are held by SVR INVEST (13%), SAFFELBERG INVESTMENTS (11.3%) and OUSIA (1.7%). It owns 35.5% of Imcyse itself.
Directors
According to the 2023 annual accounts
since 2019 · until 2025
since 2019 · until 2025
Stijn Van Rompay
Director
since 2019 · until 2025
Shareholders
Participations
35.5%
Establishments
Establishment units
Physical locations of this company
Rue Henri-Maus 78
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0500.705.585
- VAT number
- BE 0500.705.585
- Registered office
- Rue Henri-Maus 78, 4000 Liège
- Names & denominations
- BIOGENOSIS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 November 2012
- Peppol
- Not registered